Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions

Journal of the American College of Cardiology

Volumn 44, Issue 2, 2004, Pages 316-323

  Goto, Shinya ^a   Tamura, Noriko ^a   Ishida, Hideyuki ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

glycoprotein; GP; National Institutes of Health; NIH; von Willebrand factor; VWF

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; COLLAGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTEGRELLIN; TIROFIBAN;

ADULT; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DEVICE; DRUG EFFECT; DRUG MECHANISM; ELECTRICITY; HUMAN; HUMAN CELL; LYSIS; MEDICAL RECORD; PERFUSION; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE; THROMBOSIS; TIME;

ADULT; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD PLATELETS; COLLAGEN; FIBRINOLYTIC AGENTS; HEMORHEOLOGY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PIPECOLIC ACIDS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS; TYROSINE;

EID: 3242724262     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.059     Document Type: Article

References (38)

1. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696
2. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 98:1998;734-741
3. PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 338:1998;1498-1505
4. PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497
5. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443
6. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) A randomized, placebo-controlled trial. Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy. Lancet. 356:2000;2037-2044
7. Quinn M.J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa inhibitors Recognition of a two-edged sword? Circulation. 106:2002;379-385
8. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes A meta-analysis of all major randomized clinical trials. Lancet. 359:2002;189-198
9. Kleiman N.S., Raizner A.E., Jordan R., et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or α-thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab Implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol. 26:1995;1665-1671
10. Scarborough R.M., Naughton M.A., Teng W., et al. Design of potent and specific integrin antagonists Peptide antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem. 268:1993;1066-1073
11. Konstantopoulos K., Kamat S.G., Schafer A.I., et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 91:1995;1427-1431
12. Wu D., Meiring M., Kotze H.F., Deckmyn H., Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 22:2002;323-328
13. Gold H.K., Garabedian H.D., Dinsmore R.E., et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators Observations in animals and humans. Circulation. 95:1997;1755-1759
14. Yasuda T., Gold H.K., Leinbach R.C., et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol. 16:1990;1728-1735
15. Kohmura C., Gold H.K., Yasuda T., et al. Chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb. 13:1993;1837-1842
16. The SPEED Group. Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 101:2000;2788-2794
17. Antman E.M., Giugliano R.P., Gibson C.M., et al. Abciximab facilitates the rate and extent of thrombolysis Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation. 99:1999;2720-2732
18. Brener S.J., Zeymer U., Adgey A.A., et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol. 39:2002;377-386
19. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition The GUSTO V randomised trial. Lancet. 357:2001;1905-1914
20. Peerschke E.I. Stabilization of platelet-fibrinogen interactions Modulation by divalent cations. J Lab Clin Med. 121:1993;135-141
21. Kinlough-Rathbone R.L., Mustard J.F., Perry D.W., et al. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemost. 49:1983;162-167
22. Goto S. Role of von Willebrand factor for the onset of arterial thrombosis. Clin Lab. 47:2001;327-334
23. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med. 8:2002;1227-1234
24. Bhatt D.L., Topol E.J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 284:2000;1549-1558
25. Goto S., Tamura N., Handa S., Arai M., Kodama K., Takayama H. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation. 106:2002;266-272
26. Genka C., Ishida H., Ichimori K., Hirota Y., Tanaami T., Nakazawa H. Visualization of biphasic Ca2+ diffusion from cytosol to nucleus in contracting adult rat cardiac myocytes with an ultra-fast confocal imaging system. Cell Calcium. 25:1999;199-208
27. Goto S., Ikeda Y., Saldivar E., Ruggeri Z.M. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow condition. J Clin Invest. 101:1998;479-486
28. Ikeda Y., Handa M., Kawano K., et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 87:1991;1234-1240
29. Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 94:1998;657-666
30. 12) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ib-alpha induced by condition of high shear rate. Circulation. 105:2002;2531-2536
31. Mazzucato M., Pradella P., Cozzi M.R., De Marco L., Ruggeri Z.M. Sequential cytoplasmic calcium signals in a two-stage platelet activation process induced by the glycoprotein Ib mechanoreceptor. Blood. 100:2002;2793-2800
32. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a β 3 integrin-dependent mechanism. Nature Med. 8:2002;247-252
33. Collet J.P., Montalescot G., Lesty C., et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol. 21:2001;142-148
34. Back C.H., Radbill J.R., Crawford D.W. Analysis of pulsatile viscous blood flow through diseased coronary arteries of man. J Biomech. 10:1977;339-353
35. Marguerie G.A., Thomas-Maison N., Larrieu M.J., Plow E.F. The interaction of fibrinogen with human platelets in a plasma milieu. Blood. 59:1982;91-95
36. Goto S., Eto K., Ikeda Y., Handa S. Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear. Lancet. 353:1999;809
37. Goto S., Tamura N., Li M., et al. Different effects of various anti-GP IIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost. 1:2003;2022-2030
38. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894